Drug General Information (ID: DDIGUQPKE5)
Drug Name			Efalizumab		Drug Info		Daratumumab		Drug Info
Drug Type		Monoclonal antibody				Monoclonal antibody
Therapeutic Class		Immunomodulatory Agents				Antineoplastics/Cd38 Monoclonal Antibodies

Mechanism of Efalizumab-Daratumumab Interaction (Severity Level: Moderate)
Additive immunosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Efalizumab				Daratumumab
Mechanism 1		Immunosuppressive effects				Immunosuppressive effects
Key Mechanism Factor 1
		Factor Name		Immunosuppressive effects
		Factor Description		Immunosuppression is when your immune system is not functioning as it should. The immune system is made up of cells, tissues and organs that help the body fight off infections. If the immune system is suppressed, an infection that your body was able to control may become serious or even fatal.
Mechanism Description		Additive immunosuppressive effects by the combination of Efalizumab and Daratumumab
Additive myelosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Efalizumab				Daratumumab
Mechanism 2		Myelosuppressive effects				Myelosuppressive effects
Key Mechanism Factor 2
		Factor Name		Myelosuppressive effects
		Factor Description		Myelosuppression, also known as bone marrow suppression, is a decrease in bone marrow activity that leads to a decrease in the production of blood cells. Some blood cell disorders include: erythrocytopenia (anemia), leukopenia (neutropenia), and thrombocytopenia (thrombocytopenia).
Mechanism Description		Additive myelosuppressive effects by the combination of Efalizumab and Daratumumab

Recommended Action
Management		The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated. Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression. The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.

References
1	Product Information. Raptiva (efalizumab). Genentech, South San Francisco, CA.